Capsid antibodies to different adeno-associated virus serotypes bind common regions

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 9111-9124

  Gurda, Brittney L ^a,g   DiMattia, Michael A ^a,h   Miller, Edward B ^a,i   Bennett, Antonette ^a   McKenna, Robert ^a   Weichert, Wendy S ^b   Nelson, Christian D ^b,j   Chen, Wei Jun ^a   Muzyczka, Nicholas ^a   Olson, Norman H ^c   Sinkovits, Robert S ^c,k   Chiorini, John A ^d   Zolotutkhin, Sergei ^e   Kozyreva, Olga G ^f   Jude Samulski, R ^f   Baker, Timothy S ^c   Parrish, Colin R ^b   Agbandje McKenna, Mavis ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j BROWN UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; MONOCLONAL FRAGMENT ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 1; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 6; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MOLECULAR DYNAMICS; MOLECULAR IMAGING; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; SEROTYPE; THREE DIMENSIONAL IMAGING; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS IDENTIFICATION; VIRUS MORPHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BINDING SITES; CAPSID; CRYOELECTRON MICROSCOPY; DEPENDOVIRUS; EPITOPES; HUMANS; IMAGING, THREE-DIMENSIONAL; MACROMOLECULAR SUBSTANCES; MODELS, MOLECULAR; PROTEIN BINDING;

EID: 84881247172     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00622-13     Document Type: Article

References (103)

1. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD. 2000. Epitope mapping of human anti-adenoassociated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74:1761-1766.
2. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Rasko J, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12:342-347.
3. Zaiss AK, Muruve DA. 2008. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 15:808-816.
4. Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL, Wilson JM. 2011. Liver gene transfer with vectors based on adeno-associated virus 8 in non-human primates: impact of pre-existing immunity. Hum. Gene Ther. 22:1389-1401.
5. Bachmann MF, Zinkernagel RM. 1996. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today 17:553-558.
6. Dorner T, Radbruch A. 2007. Antibodies and B cell memory in viral immunity. Immunity 27:384-392.
7. Hangartner L, Zinkernagel RM, Hengartner H. 2006. Antiviral anti-body responses: the two extremes of a wide spectrum. Nature Rev. Immunol. 6:231-243.
8. Reading SA, Dimmock NJ. 2007. Neutralization of animal virus infectivity by antibody. Arch. Virol. 152:1047-1059.
9. Grieger JC, Snowdy S, Samulski RJ. 2006. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J. Virol. 80:5199-5210.
10. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt JA. 2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 80: 11040-11054.
11. Stahnke S, Lux K, Uhrig S, Kreppel F, Hosel M, Coutelle O, Ogris M, Hallek M, Buning H. 2011. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology 409:77-83.
12. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deléage G, Hallek M. 1999. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2. Nat. Med. 5:1052-1056.
13. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99:10405-10410.
14. Govindasamy L, Padron E, McKenna R, Muzyczka N, Kaludov N, Chiorini JA, Agbandje-McKenna M. 2006. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80: 11556-11570.
15. Nam H-J, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, Aslanidi G, Byrne B, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. 2007. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81:12260-12271.
16. Ng R, Govindasamy L, Gurda BL, McKenna R, Kozyreva OG, Samulski RJ, Parent KN, Baker TS, Agbandje-McKenna M. 2010. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 84:12945-12957.
17. Lerch TF, Xie Q, Chapman MS. 2010. The structure of adenoassociated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 403:26-36.
18. Chapman MS, Agbandje-McKenna M. 2006. Atomic structures of viral particles, p 107-123. In Kerr JR, Cotmore SF, Bloom ME, Linden RL, Parrish CR (ed), Parvoviruses. Edward Arnold, Ltd., New York, NY.
19. Agbandje-McKenna M, Chapman MS. 2006. Corrleating structure with function in the viral capsid, p 125-139. In Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (ed), Parvoviruses. Edward Arnold, Ltd., New York, NY.
20. Agbandje-McKenna M, Kleinschmidt J. 2011. AAV capsid structure and cell interactions. Methods Mol. Biol. 807:47-92.
21. Atchison RW, Casto BC, Hammon WM. 1965. Adenovirus-associated defective virus particles. Science 149:754-756.
22. Hoggan MD, Blacklow NR, Rowe WP. 1966. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc. Natl. Acad. Sci. U. S. A. 55: 1467-1474.
23. Parks WP, Green M, Pina M, Melnick JL. 1967. Physicochemical characterization of adeno-associated satellite virus type 4 and its nucleic acid. J. Virol. 1:980-987.
24. Bantel-Schaal U, zur Hausen H. 1984. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 134: 52-63.
25. Rutledge EA, Halbert CL, Russell DW. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72:309-319.
26. Gao G-P, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99:11854-11859.
27. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78:6381-6388.
28. Mori S, Wang L, Takeuchi T, Kanda T. 2004. Two novel adenoassociated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330:375-383.
29. Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D, Chiorini JA. 2008. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acidand heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82:1399-1406.
30. Dutta SK. 1975. Isolation and characterization of an adenovirus and isolation of its adenovirus-associated virus in cell culture from foals with respiratory tract disease. Am. J. Vet. Res. 36:247-250.
31. Farkas SL, Zadori Z, Benko M, Essbauer S, Harrach B, Tijssen P. 2004. A parvovirus isolated from royal python (Python regius) is a member of the genus Dependovirus. J. Gen. Virol. 85:555-561.
32. Bossis I, Chiorini JA. 2003. Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles. J. Virol. 77: 6799-6810.
33. Arbetman AE, Lochrie M, Zhou S, Wellman J, Scallan C, Doroudchi MM, Randlev B, Patarroyo-White S, Liu T, Smith P, Lehmkuhl H, Hobbs LA, Pierce GF, Colosi P. 2005. Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J. Virol. 79: 15238-15245.
34. Schmidt M, Grot E, Cervenka P, Wainer S, Buck C, Chiorini JA. 2006. Identification and characterization of novel adeno-associated virus isolates in ATCC virus stocks. J. Virol. 80:5082-5085.
35. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. 2006. α2,3 and α2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80:9093-9103.
36. Schmidt M, Govindasamy L, Afione S, Kaludov N, Agbandje-McKenna M, Chiorini JA. 2008. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adenoassociated virus isolate, AAV(VR-942). J. Virol. 82:8911-8916.
37. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. 2008. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16:1073-1080.
38. Mueller C, Flotte TR. 2008. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15:858-863.
39. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. 2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199:381-390.
40. Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, Aitken ML. 2006. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 17:440-447.
41. Vandenberghe LH, Wilson JM. 2007. AAV as an immunogen. Curr. Gene Ther. 7:325-333.
42. Bessis N, GarciaCozar FJ, Boissier MC. 2004. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11(Suppl 1):S10-S17.
43. Mingozzi F, High KA. 2007. Immune responses to AAV in clinical trials. Curr. Gene Ther. 7:316-324.
44. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier Bessis M-CN. 2004. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes. J. Clin. Immunol. 24:162-169.
45. Li H, Lin SW, Giles-Davis W, Li Y, Zhou D, Xiang ZQ, High KA, Ertl HCJ. 2009. A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol. Ther. 17:1215-1224.
46. Xiao W, Chirmule N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM. 2000. Route of administration determines induction of T-cellindependent humoral responses to adeno-associated virus vectors. Mol. Ther. 1:323-329.
47. Zaldumbide A, Hoeben RC. 2008. How not to be seen: immune-evasion strategies in gene therapy. Gene Ther. 15:239-246.
48. Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, Herzog RW. 2006. Prevention of cytotoxic T lymphocyte responses to factor IXexpressing hepatocytes by gene transfer-induced regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 103:4592-4597.
49. Peden CS, Burger C, Muzyczka N, Mandel RJ. 2004. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 78:6344-6359.
50. Wobus CE, Hügle-Dörr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. 2000. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74:9281-9293.
51. Kuck D, Kern A, Kleinschmidt JA. 2007. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140:17-24.
52. Harbison CE, Weichert WS, Gurda BL, Chiorini JA, Agbandje-McKenna M, Parrish CR. 2011. Examining the cross-reactivity and neutralization mechanisms of a panel of monoclonal antibodies against adeno-associated virus serotypes 1 and 5. J. Gen. Virol. 93:347-355.
53. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Buning H, Hallek M. 2003. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther. 10:2139-2147.
54. Gurda BL, Raupp C, Popa-Wagner R, Naumer M, Olson NH, Ng R, McKenna R, Baker TS, Kleinschmidt JA, Agbandje-McKenna M. 2012. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol. 86:7739-7751.
55. McCraw DM, O'Donnell JK, Taylor KA, Stagg SM, Chapman MS. 2012. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 431:40-49.
56. Kern A, Schmidt K, Leder C, Müller OJ, Wobus CE, Bettinger K, Von der Lieth CW, King JA, Kleinschmidt JA. 2003. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77:11072-11081.
57. Opie SR, Warrington KH, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77:6995-7006.
58. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2006. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80:11393-11397.
59. Excoffon KJDA, Koerber JT, Dickey DD, Murtha M, Keshavjee S, Kaspar BK, Zabner J, Schaffer DV. 2009. Directed evolution of adenoassociated virus to an infectious respiratory virus. Proc. Natl. Acad. Sci. U. S. A. 106:3865-3870.
60. DiMattia M, Govindasamy L, Levy HC, Gurda-Whitaker B, Kalina A, Kohlbrenner E, Chiorini JA, McKenna R, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. 2005. Production, purification, crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 61:917-921.
61. Miller EB, Gurda-Whitaker B, Govindasamy L, McKenna R, Zolotukhin S, Muzyczka N, Agbandje-McKenna M. 2006. Production, purification and preliminary X-ray crystallographic studies of adenoassociated virus serotype 1. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 62:1271-1274.
62. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR, Byrne BJ, Snyder RO. 2002. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158-167.
63. Martin AC, Cheetham JC, Rees AR. 1989. Modeling antibody hypervariable loops: a combined algorithm. Proc. Natl. Acad. Sci. U. S. A. 86:9268-9272.
64. Adrian M, Dubochet J, Lepault J, McDowall AW. 1984. Cryo-electron microscopy of viruses. Nature 308:32-36.
65. Dubochet J, Adrian M, Chang JJ, Homo JC, Lepault J, McDowall AW, Schultz P. 1988. Cryo-electron microscopy of vitrified specimens. Q. Rev. Biophys. 21:129-228.
66. Baker TS, Olson NH, Fuller SD. 1999. Adding the third dimension to virus life cycles: three-dimensional reconstruction of icosahedral viruses from cryo-electron micrographs. Microbiol. Mol. Biol. Rev. 63:862-922.
67. Yan X, Sinkovits RS, Baker TS. 2007. AUTO3DEM-an automated and high throughput program for image reconstruction of icosahedral particles. J. Struct. Biol. 157:73-82.
68. Gurda BL, Parent KN, Bladek H, Sinkovits RS, DiMattia MA, Rence C, Castro A, McKenna R, Olson N, Brown K, Baker TS, Agbandje-McKenna M. 2010. Human bocavirus capsid structure: insights into the structural repertoire of the Parvoviridae. J. Virol. 84:5880-5889.
69. Yan X, Dryden KA, Tang J, Baker TS. 2007. Ab initio random model method facilitates 3D reconstruction of icosahedral particles. J. Struct. Biol. 157:211-225.
70. Bowman VD, Chase ES, Franz AWE, Chipman PR, Zhang X, Perry KL, Baker TS, Smith TJ. 2002. An antibody to the putative aphid recognition site on cucumber mosaic virus recognizes pentons but not hexons. J. Virol. 76:12250-12258.
71. Zhang X, Walker SB, Chipman PR, Nibert ML, Baker TS. 2003. Reovirus polymerase lambda 3 localized by cryo-electron microscopy of virions at a resolution of 7.6 Å. Nat. Struct. Biol. 10:1011-1018.
72. van Heel M, Schatz M. 2005. Fourier shell correlation threshold criteria. J. Struct. Biol. 151:250-262.
73. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
74. Chacon P, Wriggers W. 2002. Multi-resolution contour-based fitting of macromolecular structures. J. Mol. Biol. 317:375-384.
75. Emsley P, Cowtan K. 2004. COOT: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
76. Kleywegt GJ, Jones TA. 1996. xdlMAPMAN and xdlDATAMAN-programs for reformatting, analysis and manipulation of biomacromolecular electron-density maps and reflection data sets. Acta Crystallogr. D Biol. Crystallogr. 52:826-828.
77. Suh SW, Bhat TN, Navia MA, Cohen GH, Rao DN, Rudikoff S, Davies DR. 1986. The galactan-binding immunoglobulin Fab J539: an X-ray diffraction study at 2.6-Å resolution. Proteins 1:74-80.
78. Strong RK, Campbell R, Rose DR, Petsko GA, Sharon J, Margolies MN. 1991. Three-dimensional structure of murine anti-pazophenylarsonate Fab 36-71. 1. X-ray crystallography, site-directed mutagenesis, and modeling of the complex with hapten. Biochemistry 30:3739-3748.
79. Guddat LW, Shan L, Broomell C, Ramsland PA, Fan Z, Anchin JM, Linthicum DS, Edmundson AB. 2000. The three-dimensional structure of a complex of a murine Fab (NC10.14) with a potent sweetener (NC174): an illustration of structural diversity in antigen recognition by immunoglobulins. J. Mol. Biol. 302:853-872.
80. Goddard TD, Huang CC, Ferrin TE. 2007. Visualizing density maps with UCSF Chimera. J. Struct. Biol. 157:281-287.
81. Heymann JB, Belnap DM. 2007. Bsoft: image processing and molecular modeling for electron microscopy. J. Struct. Biol. 157:3-18.
82. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486-501.
83. Brooks CL, Blackler RJ, Sixta G, Kosma P, Muller-Loennies S, Brade L, Hirama T, MacKenzie CR, Brade H, Evans SV. 2010. The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen. Glycobiology 20:138-147.
84. Krissinel E, Henrick K. 2007. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372:774-797.
85. Kaufmann B, López-Bueno A, Mateu MG, Chipman PR, Nelson CDS, Parrish CR, Almendral JM, Rossmann MG. 2007. Minute virus of mice, a parvovirus, in complex with the Fab fragment of a neutralizing monoclonal antibody. J. Virol. 81:9851-9858.
86. Hafenstein S, Bowman VD, Sun T, Nelson CDS, Palermo LM, Chipman PR, Battisti AJ, Parrish CR, Rossmann MG. 2009. Structural Comparison of Different Antibodies Interacting with Parvovirus Capsids. J. Virol. 83:5556-5566.
87. Smith TJ. 2003. Structural studies on antibody-virus complexes. Adv. Protein Chem. 64:409-453.
88. Xie Q, Lerch TF, Meyer NL, Chapman MS. 2011. Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV6). Virology 420:10-19.
89. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, Pierce GF, Colosi P. 2006. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80:821-834.
90. Stanfield RL, Zemla A, Wilson IA, Rupp B. 2006. Antibody elbow angles are influenced by their light chain class. J. Mol. Biol. 357:1566-1574.
91. Law M, Hangartner L. 2008. Antibodies against viruses: passive and active immunization. Curr. Opin. Immunol. 20:486-492.
92. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
93. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2006. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 80:8961-8969.
94. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75:6884-6893.
95. Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J. 2001. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276:20610-20616.
96. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286:13532-13540.
97. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9:1306-1312.
98. Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. 1997. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71:1341-1352.
99. Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K, Warrington K, Chen W, Muzyczka N, Yan X, Baker TS, Agbandje-McKenna M. 2009. Heparin binding induces conformational changes in adeno-associated virus serotype 2. J. Struct. Biol. 165:146-156.
100. O'Donnell J, Taylor KA, Chapman MS. 2009. Adeno-associated virus-2 and its primary cellular receptor: cryo-EM structure of a heparin complex. Virology 385:434-443.
101. Li W, Zhang L, Johnson JS, Zhijian W, Grieger JC, Ping-Jie X, Drouin LM, Agbandje-McKenna M, Pickles RJ, Samulski RJ. 2009. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol. Ther. 17: 2067-2077.
102. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. 2009. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol. Ther. 17:294-301.
103. Xiao C, Rossmann MG. 2007. Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 158:182-187.